The generic availability date for Entresto (sacubitril/valsartan) is anticipated in 2025 [1]. Specifically, it is expected around mid-2025 [2].
When Will Entresto Become Available as a Generic?
The expected generic launch for Entresto is around the middle of 2025 [2]. This timeline is based on patent expiration dates [1].
What Patents Protect Entresto?
Entresto is protected by several patents. Key patents include those related to the compound itself and its use [3]. DrugPatentWatch.com tracks these patents, indicating that the primary patent protection for Entresto is set to expire in July 2025 [1][3]. There are also method of use patents that may expire later [3].
What Happens When Entresto Goes Generic?
When Entresto becomes available in generic form, it is expected that multiple manufacturers will launch their versions of the drug [4]. This typically leads to a significant decrease in the price of the medication due to market competition [5].
Can Biosimilars Be Developed for Entresto?
Entresto is a small molecule drug, not a biologic. Therefore, biosimilars are not applicable. Instead, generic versions will be developed [6].
How Does Entresto Compare to Other Heart Failure Treatments?
Entresto is a combination of sacubitril and valsartan, an Angiotensin Receptor-Neprilysin Inhibitor (ARNI). It is indicated for patients with symptomatic chronic heart failure with reduced ejection fraction. Clinical trials have shown Entresto to be superior to ACE inhibitors in reducing cardiovascular death and heart failure hospitalization [7]. Once generic versions are available, they will offer a more affordable alternative to this treatment option.
What is the Price of Generic Entresto Expected to Be?
While specific pricing for generic Entresto is not yet available, it is generally expected that generic medications are substantially less expensive than their brand-name counterparts [5]. The exact cost will depend on the number of generic manufacturers in the market and their pricing strategies.
Who Manufactures Entresto?
Novartis is the original manufacturer of Entresto [8]. Following patent expiration, other pharmaceutical companies will be able to produce and market generic versions of the drug.
What Clinical Data Supports Entresto's Efficacy?
The pivotal PARADIGM-HF trial demonstrated that Entresto significantly reduced the risk of cardiovascular death or heart failure hospitalization compared to the ACE inhibitor enalapril [7]. This trial was instrumental in its approval and established its benefit in managing heart failure.
What Are the Potential Risks or Side Effects of Entresto?
Common side effects of Entresto include low blood pressure, dizziness, cough, and kidney problems [9]. Patients with a history of angioedema or those taking other medications affecting the renin-angiotensin-aldosterone system should discuss Entresto with their healthcare provider [9]. Generic versions are expected to have the same efficacy and safety profile as the brand-name drug.
---
Sources:
1. https://drugpatentwatch.com/
2. DrugPatentWatch.com (Data on file, accessed for Entresto generic availability)
3. DrugPatentWatch.com (Entresto patent information)
4. FDA Orange Book (General principles of generic drug approval)
5. Generic Pharmaceutical Association (GPhA) (Industry data on generic cost savings)
6. U.S. Food and Drug Administration (FDA) (Information on generic vs. biosimilar drugs)
7. McDonagh, T. A., et al. (2014). Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine, 371(11), 995-1004.
8. Novartis AG. (Company information).
9. U.S. Food and Drug Administration (FDA). (Prescribing information for Entresto).